anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
M-CARES uses a randomized control trial design to assess the effects of providing free contraception to mothers on their children born before the intervention. The population subject to intervention is fecund women age 18-35 years at risk of pregnancy and who are clients at Planned Parenthood clinics of Michigan (PPMI), who meet income eligibility criteria, and who would otherwise pay out-of-pocket for services on the day of recruitment (i.e., lacking insurance coverage for received service). The experimental (treatment) condition is a mother's receipt of a voucher providing access to no-cost contraception (up to the price of a name-brand intrauterine device) for 100 days. The control group of mothers receives no voucher. All enrolled women complete a two-part baseline survey and consent to be re-contacted for two follow-up interviews in outgoing years. They also complete a two-part baseline survey and consent to be re-contacted for two follow up interviews in outgoing years. In addition, mothers consent to linkages to their own and their children's administrative data from records held by state and federal health, education, criminal justice, and tax records. Consent covers children already born to women at the time of intervention and children born after intervention. Survey and administrative data provide outcome measures to assess children's well-being and development up to age 18. The study will compare children of mothers who receive the intervention to those who did not.
Tinostamustine as a single agent administered at a dose of 100mg/m2 by IV infusion over 60min on D1 of 21-day cycle. Patients are of subtypes mycosis fungoides (MF) or Sézary syndrome (SS).
OBJECTIVE: Chronic heart failure (CHF) management requires a multidisciplinary approach, and it's very important for primary care physicians (PCC) to cooperate with cardiology physicians in this process. In this study, we tried to reveal the awareness and expectations of PCC about CHF management.
METHODS: The study was designed as a descriptive survey in a single region and included 549 PCC. Data were collected through a survey study.
RESULTS: A total of 389 PCC participated in our study. Of these, 137 (35.2%) stated that they had an average of more than 40 CHF patients registered with them, and 331 (85.1%) stated that they had identified them thanks to their medical treatment. The symptoms that physicians most frequently question in CHF patients are shortness of breath (27.5%), swelling in the ankle (27%), orthopnea (23.9%) and palpitations (20.5%). The physical examination findings that they question most frequently are peripheral edema (% 29.2), tachycardia (18.5%), crepitus in the lungs (16.8%), and irregular pulse (15.2%). 203 (55.9%) of PCC stated that measurements of natriuretic peptides could be implemented in their institutions if the necessary training and opportunity were provided. Most physicians (46.8%) stated that they should be given priority in referring CHF patients; 172 of them (44.2%) stated that they received in-service training regarding CHF and 278 of them (71.5%) stated that their training was not at a sufficient level.
CONCLUSION: It is clear that better results can be obtained in the management of CHF as the education level and professional experience of PHCs increases. It seems that PCC need training on CHF and need to improve the quality of communication with cardiologist's.
Peanuts are a common cause of food hypersensitivity reactions. The sera of 10 patients who had atopic dermatitis and a positive double-blind placebo-controlled food challenge to peanut were used to investigate the major allergens of peanut. Crude Florunner extracts were fractionated by anion-exchange chromatography using a step gradient (limit buffer, 0.05M BisTris/1.5M NaCl). A protein peak (OD 280) which eluted at 10t NaCl and demonstrated intense IgE-binding was further analyzed by two-dimensional SDS-PAGE/immunoblot analysis. The majority of this fraction is a protein which has a molecular weight of 17 kD and a pI of 5.2. Sequencing data from the N-terminus revealed the following initial 9 amino acids: (*)-Q-Q-(*)-E-L-Q-D-L. Based on IgE-binding activity and no known amino acid sequence identity to other allergens, this allergen is designated Ara h II. Ara h II may be used to detect and quantify peanut allergens in foodstuffs. Serum IgE from patients with documented peanut hypersensitivity reactions and a peanut cDNA expression library were used to identify clones that encode peanut allergens. One of the major peanut allergens, Ara h I, was selected from these clones using Ara h I specific oligo-nucleotides and polymerase chain reaction technology. The Ara h I clone identified a2.3 kb mRNA species on a Northern blot containing peanut poly A+RNA. DNA sequence analysis of the cloned inserts revealed that the Ara h I allergen has significant homology with the vicilin seed storage protein family found in most higher plants. The isolation of the Ara h I clones allowed the synthesis of this protein in E. coli cells and subsequent recognition of this recombinant protein in immunoblot analysis using serum IgE from patients with peanut hypersensitivity.
NEW MATERIAL:Acylated anthocyanin of formula I, wherein R1 is H, caffeic acid or ferulic acid; R2-R4 are each caffeic acid or ferulic acid. EXAMPLE:3-0-beta-D-Glucopyransoyl-7-0-(6-0-Caffeyl-beta-D-glucopyran soyl)-3'-0-(6-0-Ca ffeyl-beta-D-glucopyransoyl)cyanidin of formula II. USE:Dyes which have excellent resistance to acids, alkalis, heat and weather and which dye foods, pharmaceutical preparations, etc., reddish purple to blue. PREPARATION:The flower, the leaves and the stem, of Zebrina pendula of the family Commelinaceae are freeze-crushed and dissolved in a methanol soln. contg. hydrochloric acid or trifluoroacetic acid. The soln. is filtered and dried in vacuo to obtain anthocyanin as an oil. Anthocyanin is purified by high performance chromatography with a reversed phase partition column.
PURPOSE: A method for producing recombinant virus is based on the use of baculovirus for providing the complementary functions. Constructs used for implementing this method, the production cells, and the resulting virus are provided. CONSTITUTION: A viral vector is widely used for gene cloning, transferring, and expressing in vitro (preparing an animal testing model, therapeutic approaching and such like) and also in vivo (producing a recombinant protein, performing screening, study for gene regulation and such like). Deleted recombinant virus is produced by introducing genome of deleted recombinant virus or vaculovirus comprising essential complementary functions into a competent cell. The new production system neither involves RCA problems nor complementary cell lines. Also, it is applicable to a cell capable of being infected by desired virus or baculovirus.
We are conducting a pilot study among 240 young Black MSM and transgender women randomized to the Intervention Arm (assessment and algorithm to deliver a tailored recommendation) or Control (assessment and standard HIV testing information) and followed for 6 months to estimate the intervention's potential efficacy in increasing HIV testing. After informed consent, participants are asked to provide contact information on the locator form. Then, participants complete a brief quantitative assessment including basic demographics, HIV testing history and other factors related to HIV testing. All participants, regardless of study arm, then receive information about each HIV testing method including how the tests are conducted (blood, oral sample), and availability of counseling and support. Participants then are randomized into 1 of the 2 study arms. A computer program will randomly assign each participant using randomly ordered block sizes of 4 and 6 and stratified by age (16-23, 24-29 years) to balance groups.

Participants assigned to the Intervention Arm will complete a brief quantitative assessment lasting approximately 2-3 minutes to assess those factors associated with HIV testing and thus are needed to complete the algorithm. They then receive the results of the HIV testing algorithm, presented as their personalized HIV testing approach. All participants will receive information on resources in New York City to test by all of these methods. The control participants are provided with the above information about each testing approach but without a recommended approach.
Active treatment subjects will be asked to sit on the center of the Emsella chair. The height of the chair will be adjusted until the participant's feet are on the floor. The Emsella chair will be turned on and the setting gradually increased to the subject's sensory threshold; the maximum sensation the subject can tolerate. The setting will then be decreased slightly and stay unchanged for the remainder of the treatment time. The treatment threshold should be increased with every treatment until the subject reaches 100%.
The primary objective of this study is to verify the acceptability of the GUARDIAN platform by the elderly, detected through the scale Unified Theory of Acceptance and Use of Technology (UTAUT). The aim of this project is to enable the older adult to live as long as possible at home, involving the informal caregiver, using the available technologies. The GUARDIAN platform consists of the Senior App, the Caregiver App and the Misty II robot. The Senior App is an easy-to-use application that will ask the elderly for health status, whether they have carried out their daily activities, if they have taken pre-establishable drugs and if they have eaten properly. The application will generate self-reports that will be transmitted to the app caregiver. The elderly can answer the questions via a tablet on the robot or by voice. The Caregiver App is the application intended for the caregiver, in which you can set up reminders for the elderly about meals or drugs, send communications and ask for reports on his health. This application will be used by both the informal caregiver and the formal caregiver (health care professional). It is the social robot that will complete the platform. Reminders will be sent via the robot and questions will be asked to the patient. The trial will consist of two phases involving, in each of the three participant countries (Italy, Nederlands and Switzerland), 4 seniors with their informal caregivers in the Alpha phase and 10 seniors with their informal caregivers in the following GUARDIAN trial. In both phases the presence of a formal caregiver is expected. In the Alpha phase 4 users and their caregivers will use a first version of the GUARDIAN platform, for three months. The results and feedback from the Alpha phase will give indications to improve and refine the platform.

The GUARDIAN trial involves the enrollment of 10 elderly people in each of the three participant countries (different from those recruited in the Alpha phase) and their respective informal caregivers. The evaluations will be carried out at baseline (T0) and then every month, for three months (T1, T2, T3).
The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin. To date, all adverse effects of tretinoin have been reversible upon discontinuance of therapy (see DOSAGEAND ADMINISTRATION ). 

To report SUSPECTED ADVERSE REACTIONS, contact Mylan at 1-877-446-3679   
(1-877-4-INFO-RX) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
If a patient or their caregivers choose no tooth-specific treatment, they will be included in the control cohort. This group includes patients who chose to receive no treatment at all, as well as those who choose whole mouth treatments such as: 2.26% fluoride varnish, 1.23% fluoride foam, and 5000 ppm fluoride prescription toothpaste.
The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV  envelope proteins are characterized in that on average up to 80 % of their N-glycosylation sites are core-glycosylated. Of these N-glycosylated sites more than 70 % are glycosylated with an oligomannose containing 8 to 10 mannoses.  Furthermore, the ratio of the oligomannoses with structure Man(7)-GlcNAc(2) over the oligomannose with structure Man(8)-GlcNAc(2) is less than or equal to 0.45. Less than 10 % of the oligomannoses is terminated with an .alpha.1,3 linked mannose. The HCV envelope proteins of the invention are particularly suited for diagnostic, prophylactic and therapeutic purposes. A suitable eukaryotic cell for production of the HCV envelope proteins of the invention is a Hansenula cell.
The research question is: does the use of Aspirin alone compared to using Aspirin along with a mobile compression device provide equivocal results for preventing Deep Vein Thrombosis (DVT) and pulmonary embolism (PE) after total joint arthroplasty? Participants were randomized to either receive aspirin and mobile pneumatic compression devices or aspirin alone as outpatient DVT prophylaxis as their standard of care after primary total hip and total knee arthroplasty. Participants randomized to the compression device group were asked to wear the compression devices for 20 hours a day for 2 weeks along with taking an aspirin (325mg once a day), per standard of care. Participants randomized to aspirin alone took 325 mg per day. Participant usage information from Active Care +S.F.T. mobile devices was collected. The information was recorded at the participant's first follow up visit occurring between 7-21 days post-surgery. All of the participants were asked to keep a checklist indicating aspirin intake compliance each day, which was returned at their first follow up visit. Participants randomized to mobile pneumatic compression device and aspirin (325 mg) were asked to complete a satisfaction questionnaire about the compression device at their first follow up visit. Participants received a phone call from a member of the research team approximately 90 days post-op. The call was necessary to assess if any participants have been diagnosed with DVT at another hospital.
The Sham electroacupuncture therapy protocol(Non-acupoint, No electrical stimulation)included the same number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment, but superficially at non acupuncture points 15 mm to the lateral of each acupuncture point was treated. The points were not stimulated electrically, but the sound of the pulse generator was heard by the participants. (Lee SH, LeeBC 2009) Those receiving EA or SEA therapy were treated on alternate days to prevent crosstalk among groups, which could have compromised the blinded study design.
The invention discloses a Chinese medicine for curing cholecystitis, at least comprising the following five medicinal materials in weigh shares: Pothos repens (Lour.)Merr 3-30 shares, Shansuan 3-20 shares, Mongolian Dandelion Herb 2-20 shares, Asiatic Pennywort Herb 3-30 shares, and Chinese Fevervine Herb 3-20 shares. And it can be made into soup, decoction, pills, tablets, capsules and other forms, where the tablets are better. It has rapid curative effect, and remarkable effect, able to faster cure patients. Ordinarily, a patient can be basically cured within half a month or so. And it has better curative effects of diminishing inflammation, benefiting gallb ladder and reducing cholesterin on patients with cholecystitis, able to treat both principal and secondary aspect of disease, and after the patient is cured, the cholecystitis is uneasy to recur.
Dose escalation phase- 12 subjects in Cohort 2, Palbociclib dose escalation will begin at 75 mg/m2/day, on Days 1 to 5; 11 to 15; and 21 to 30, and escalate or de escalate. All subjects will receive palbociclib with dexamethasone, bortezomib, and doxorubicin. dexamethasone of each 30 day cycle for up to 3 cycles for responders which include complete remission, complete remission morphologic, and partial response as defined in section 10.2.1. Bortezomib will be given on Days 7, 10, 17 and 20. Doxorubicin will be given on Days 7 and 17. Subjects with Ph+ / Ph-like mutation will receive a tyrosine kinase inhibitor (TKI or KI, either dasatinib or ruxolitinib).3 on 3 dose escalation with 2 dose levels.
Hepatitis C virus (HCV) infection is a global health problem, which may lead to chronic hepatitis, cirrhosis, hepatic decompensation and hepatocellular carcinoma (HCC). \[1,2\] Recently, treatment with peginterferon alfa plus ribavirin has become the standard of care for patients with chronic hepatitis C. While genotype 2 patients can have higher sustained virologic response (SVR) rates to 80-90%, genotype 1 patients generally have low SVR rates of only 40-50%. \[3-5\] In contrast, genotype 1 Taiwanese patients have superior SVR rates that those in Western countries. \[6,7\] Despite the overall improved response to this combination therapy, more than 75% of patients suffer from treatment-related adverse events and the costs remain high, \[8,9\] which make individualized therapy of paramount importance to maximize treatment response and minimize adverse events.

HCV viral kinetics with interferon-based therapies have been studied recently to evaluate patient responses. \[10-14\] Early viral kinetics shown to have favorable SVR rates, which make shorter treatment duration possible. \[15-18\] However, different viral kinetics were found through ethnicity. \[19-23\] Recently, a pilot study to evaluate the viral kinetics of 6 Taiwanese patients with HCV infection who received peginterferon alfa plus ribavirin therapy has shown superior early viral kinetics to those in Caucasian patients. \[24\] Based on the favorable SVR rates in treating Taiwanese patients with chronic hepatitis C, the investigators aimed to conduct a large confirmatory study to evaluate the viral kinetics and try to define the optimal treatment for these patients.
1. From an initial dose, closely follow patients and change the dosage strength until the patient reaches a dose that provides adequate analgesia with tolerable side effects. Patients should record their use of fentanyl buccal tablet/s over several episodes of breakthrough pain and discuss their experience with their healthcare provider to determine if a dosage adjustment is warranted.
  2. Patients whose initial dose is 100 mcg and who need to titrate to a higher dose, can be instructed to use two 100 mcg tablets (one on each side of the mouth in the buccal cavity) with their next breakthrough pain episode. If this dosage is not successful, the patient may be instructed to place two 100 mcg tablets on each side of the mouth in the buccal cavity (total of four 100 mcg tablets). Titrate using multiples of the 200 mcg fentanyl buccal tablet for doses above 400 mcg (600 mcg and 800 mcg). Note: Do not use more than 4 tablets simultaneously.
  3. In cases where the breakthrough pain episode is not relieved after 30 minutes, patients may take ONLY ONE additional dose of the same strength for that episode. Thus patients should take a maximum of two doses of fentanyl buccal tablet for any breakthrough pain episode. During titration, one dose of fentanyl buccal tablet may include administration of 1 to 4 tablets of the same dosage strength (100 mcg or 200 mcg).
  4. Patients MUST wait at least 4 hours before treating another episode of breakthrough pain with fentanyl buccal tablet. To reduce the risk of overdose during titration, patients should have only one strength of fentanyl buccal tablet/s available at any time.
  5. Patients should be strongly encouraged to use all of their fentanyl buccal tablets of one strength prior to being prescribed the next strength. If this is not practical, unused fentanyl buccal tablets should be disposed of safely [see How Supplied/Storage and Handling (16)]. Dispose of any unopened fentanyl buccal tablets remaining from a prescription as soon as they are no longer needed.
The present invention provides an anti-cancer lipid-based composition that kills very aggressive pancreatic cancer cells and breast cancer stem cell (CSC)-like cells. This composition is a concoction of an anti-cancer agent, ESC8 and a glucocorticoid receptor (GR)-targeting cationic lipid delivery system, DX which is further complexed with plasmid DNA. This composition shows anti-cancer effect and initiates killing of cancer cells and CSC-like cells within 3h. When anti-cancer gene encoded plasmid is used, residual cancer cells were also significantly eradicated after 2 days of exposure. The formulation-free naked ESC8 requires at least ten-fold more concentration and 3 days of continuous treatment to get a similar level of killing. The composition could also inhibit the tumor growth in mice orthotopically implanted with very aggressive mouse breast cancer cell, ANV-1. This cell is known to produce breast CSC- like cells that show phenotype of advanced cancer relapsing. There is no visible toxic effect of this composition when injected in mice, indicating that it has minimum to no toxic effect to normal homeostasis. The present invention is likely to find specific application in developing potential therapeutic treatment for aggressive cancers and CSC-like cancers.
Potential interactions between oxcarbazepine and other AEDs were assessed in clinical studies. The effect of these interactions on mean AUCs and C min are summarized in Table 7.

In vivo, the plasma levels of phenytoin increased by up to 40% when oxcarbazepine was given at doses above 1200 mg/day. Therefore, when using doses of oxcarbazepine greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of phenytoin may be required. The increase of phenobarbital level, however, is small (15%) when given with oxcarbazepine.

Strong inducers of cytochrome P450 enzymes (i.e., carbamazepine, phenytoin and phenobarbital) have been shown to decrease the plasma levels of MHD (29% to 40%).

No autoinduction has been observed with oxcarbazepine.